6-oxoazepinoindole compounds, and pharmaceutical compositions containing them

US5272143A · kind A · utility

Assignee

• Kali-Chemie Pharma GmbH · DE

Inventors

• Werner Benson · Hannover, DE
• Karin Juliette Van Charldorp · Hilversum, NL
• Peter-Colin Gregory · Hannover, DE
• Klaus-Ullrich Wolf · Burgdorf, DE
• Ulf Preuschoff · Laatzen, DE
• Martin Tulp · Weesp, NL
• Ton Hulkenberg · Bunschoten-Spakenburg, NL
• Ineke van Wijngaarden · Weesp, NL

Key dates

• Filing date: Jul 31, 1992
• Grant date: Dec 21, 1993
• Expiry date: Jul 31, 2012

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D209/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Pharmacologically active compounds corresponding to the general formula I ##STR1## in which R.sup.1 represents hydrogen, a lower alkyl or cycloalkyl-alkyl group or an optionally substituted phenyl-lower alkyl group, PA1 R.sup.2 denotes hydrogen or a lower alkyl group optionally substituted in the .alpha.-position to the nitrogen atom by lower alkoxy, PA1 R.sup.3 denotes hydrogen, lower alkyl, lower alkoxy, halogen or hydroxyl, PA1 n represents 1 or, if the --(CH.sub.2).sub.n -- chain is in the 4-position of the ring structure, also represents 2, PA1 R.sup.4 denotes hydrogen, lower alkyl, cycloalkyl, cycloalkyl-lower alkyl or an optionally substituted phenyl-lower alkyl group, and PA1 R.sup.5 denotes hydrogen, lower alkyl, cycloalkyl, cycloalkyl-lower alkyl or an optionally substituted phenyl-lower alkyl group, or PA1 R.sup.4 and R.sup.5, together with the nitrogen atom to which they are bonded, form a heterocycle and PA1 D represents a bond, or, if R.sup.4 and R.sup.5 do not denote hydrogen, also represents the --N.dbd.CH-- group, and their physiologically acceptable acid addition salts are described, and also processes and intermediates for their preparation.